LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright

LAVA Therapeutics (NASDAQ:LVTX)‘s stock had its “neutral” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $1.50 target price on the stock. HC Wainwright’s target price points to a potential upside of 16.28% from the company’s current price.

LVTX has been the topic of several other reports. Leerink Partners reiterated a “market perform” rating and issued a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. JMP Securities reissued a “market perform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partnrs downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Citizens Jmp lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $3.17.

LAVA Therapeutics Price Performance

Shares of LAVA Therapeutics stock opened at $1.29 on Monday. The stock has a market capitalization of $33.92 million, a price-to-earnings ratio of -1.25 and a beta of 0.48. The business has a 50-day moving average of $1.13 and a 200 day moving average of $1.37. LAVA Therapeutics has a 12 month low of $0.85 and a 12 month high of $3.57.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.18. The business had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $2.40 million. Equities research analysts anticipate that LAVA Therapeutics will post -1.13 earnings per share for the current year.

Hedge Funds Weigh In On LAVA Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in shares of LAVA Therapeutics during the 3rd quarter worth approximately $32,000. BNP Paribas Financial Markets acquired a new stake in LAVA Therapeutics during the 4th quarter worth $40,000. Finally, Sanofi purchased a new stake in LAVA Therapeutics in the fourth quarter valued at $1,825,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.